Gene therapy for pulmonary diseases. Review uri icon

Overview

MeSH

  • Adenoviridae
  • Humans
  • Recombination, Genetic
  • Retroviridae

MeSH Major

  • Cystic Fibrosis
  • Deficiency Diseases
  • Gene Transfer Techniques
  • Genetic Therapy
  • alpha 1-Antitrypsin Deficiency

abstract

  • The common fatal hereditary disorders, alpha 1-antitrypsin (alpha 1AT) deficiency and cystic fibrosis (CF), are clinical models for the common lung diseases, emphysema and chronic bronchitis, respectively. Both are potentially amenable to therapeutic intervention by gene therapy, in which the relevant gene is used to modify cells of the affected individual. Although the gene therapy strategies for these diseases are conceptually quite different, a promising approach for both is the in vivo administration of a recombinant replication deficient adenovirus vector containing a normal copy of the abnormal gene. If the goal is to express the normal extracellular anti-protease alpha 1 AT, the route of administration could be directly into the lung, liver or vascular endothelium. If the goal is to express the normal transmembrane protein defective in CF epithelial cells, the new gene will need to be delivered directly to the affected cells. The feasibility of these approaches has been demonstrated in vitro and in vivo in experimental animals.

publication date

  • October 1993

has subject area

  • Adenoviridae
  • Cystic Fibrosis
  • Deficiency Diseases
  • Gene Transfer Techniques
  • Genetic Therapy
  • Humans
  • Recombination, Genetic
  • Retroviridae
  • alpha 1-Antitrypsin Deficiency

Research

keywords

  • Journal Article
  • Review

Identity

Language

  • eng

PubMed ID

  • 8290311

Additional Document Info

start page

  • 677

end page

  • 680

volume

  • 41

number

  • 8